Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2021
Third quarter (July–September 2021) · Operating loss totaled SEK -6,753,799 (-216,550). · Loss for the period totaled SEK -6,753,799 (-211,132). · Cash flow from operating activities totaled SEK -13,418,888 (-104,589). · Earnings per share before dilution totaled SEK -0.34 (-0.02). Earnings per share after dilution amounted to SEK -0.34 (-0.02). Period (January–September 2021) · Operating loss totaled SEK -10,977,101 (-232,020). · Loss for the period totaled SEK -10,978,176 (-226,601). · Cash flow from operating activities totaled SEK -13,413,256 (-122,627). ·